Prexigebersen is under clinical development by Bio-Path and currently in Phase II for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia). According to GlobalData, Phase II drugs for Acute ...

ES-3000 is under clinical development by Escend Pharmaceuticals and currently in Phase II for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia). According to GlobalData, Phase II drugs for ...

Although treatment with single-agent ATRA during induction results in CR rates of 72–90%, [10–13] patients who achieve CR initially with ATRA alone generally relapsed without additional ...

Leukemia is defined as a progressive, malignant (spreading) cancer that affects the blood-forming organs, of which there are several involved. The cancer changes the growth and development of ...

Jan. 14, 2025 — A team of researchers has developed a new biomaterial with high potential in in the treatment of bone lesions or minimal residual disease in multiple myeloma patients. The ...

Even so, the diseases can have episodic flares in which acute symptoms spontaneously develop and disappear. While acute conditions are technically those that begin suddenly without preexisting ...

CNET’s expert staff reviews and rates dozens of new products and services each month, building on more than a quarter century of expertise.

and outcomes of patients presenting without chest pain across different diagnostic categories of ACS. Design and Setting: The Global Registry of Acute Coronary Events is a multinational ...